Carnitor (Levocarnitine)

Brand Name

Carnitor

Generic Name

Levocarnitine

View Brand Information

FDA approval date: December 27, 1985

Classification: Carnitine Analog

Form: Injection, Tablet, Solution

What is Carnitor (Levocarnitine)?

CARNITOR ® is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation. In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. CARNITOR ® is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

The Effects of Carnitine Supplementation on Oocyte Yield and Quality in Women Undergoing IVF

Enrollment Status: Recruiting

Publish Date: August 24, 2026

Intervention Type: Dietary supplement

Study Phase: Not Applicable

Summary: The goal of this clinical trial is to learn whether supplementation with L-carnitine improves outcomes in women undergoing in vitro fertilization (IVF). It will also evaluate the effect of supplementation on oocyte quality, embryo quality, and pregnancy rates. The main questions it aims to answer are: * Does supplementation improve the number and quality of oocytes retrieved during IVF treatment? ...

The Effect of L-Carnitine on Wound Healing in Patients With Diabetic Foot Ulcer.

Enrollment Status: Recruiting

Publish Date: August 17, 2026

Intervention Type: Drug

Study Phase: Phase 2

Summary: Primary outcome: To evaluate the efficacy of L-Carnitine supplementation on length and depth ulcer size Secondary outcome: To investigate the effect of L-Carnitine supplements on: 1. Vascular endothelial growth factor (VEGF) 2. Inflammatory markers TNF-a (Tumor necrosis factor alpha). 3. Hemoglobin A1C (HbA1c) And Lipid profile (cholesterol, triglycerides, high-density Lipoprotein (HDL) and low-de...

Evaluation of the Clinical Impact of Adjunctive L-carnitine Therapy in Critically Ill Hepatic Patients Admitted to Intensive Care Unit

Enrollment Status: Recruiting

Publish Date: July 21, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: This study aims to evaluate the possible efficacy of l-carnitine in critically ill hepatic patients admitted to intensive care unit.

View All Clinical Trials

Related Latest Advances

Micronutrients in adult critically ill patients: lessons learned and the path toward precision.

Journal: Current opinion in clinical nutrition and metabolic care

Published: September 02, 2026

Development and evaluation of dried blood spot quality control materials in newborn screening for inborn errors of metabolism.

Journal: The Analyst

Published: August 27, 2026

Environmental risk factors for false-positive results in newborn screening for primary carnitine deficiency: a multicenter large-scale retrospective cohort study.

Journal: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

Published: August 27, 2026

View All Latest Advances